The National Health Surveillance Agency (ANVISA) in Brazil has approved the use of the monoclonal antibody Remsima (infliximab) from Hospira Inc. and its partner Celltrion. Remsima is responsible for the treatment of, “rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn’s disease in adults and children, fistulizing Crohn’s disease (advanced), colitis and ulcerative rectocolitis.” This … Continue reading ANVISA Approves First Infliximab Biosimilar in Brazil
Read more